Tuesday, November 25, 2008

Parexel Completes Chinese Bridging Study

According to this article in Clinical Trials Today, the contract research organization Parexel has completed a Chinese bridging study to be conducted outside of China at their Los Angeles facility. Parexel recently acquired California Clinical Trials (CCT), which does a number of ethnobridging studies.

Michelle Middle, corporate vice president and worldwide head of Clinical Pharmacology at Parexel mentions:

“The goal of Parexel clinical pharmacology is to help sponsors to get as much information as soon as possible in drug development.”

Briding studies have grown increasingly important to clinical research, as more and more companies are looking to cut back on costs.

No comments:

Post a Comment